SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 160.10 |
| Enterprise Value ($M) | 142.94 |
| Book Value ($M) | 68.44 |
| Book Value / Share | 0.30 |
| Price / Book | 2.34 |
| NCAV ($M) | -31.78 |
| NCAV / Share | -0.14 |
| Price / NCAV | -5.04 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.79 |
| Return on Assets (ROA) | -0.79 |
| Return on Equity (ROE) | -1.25 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.83 |
| Current Ratio | 0.83 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 66.46 |
| Assets | 166.67 |
| Liabilities | 98.23 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Vanguard Group Inc | 4.63 | 0.36 | |
| 13G | Ra Capital Management, L.p. | 9.10 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 110,272 | 615,560 | 17.91 | |
| 179,667 | 1,102,043 | 16.30 | |
| 259,215 | 1,159,032 | 22.36 | |
| 121,678 | 615,673 | 19.76 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| VSTM – Verastem, Inc. | VTGN – Vistagen Therapeutics, Inc. |
| VTVT – vTv Therapeutics Inc. | VYNE – VYNE Therapeutics Inc. |
| WINT – Windtree Therapeutics, Inc. |